Smoking Cessation Program in the Construction Sector
Launched by UNIVERSITY OF MIAMI · Oct 18, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring the best way to help construction workers quit smoking. It aims to find an effective and cost-efficient smoking cessation program tailored specifically for the construction industry. The study is currently looking for participants, including company leaders, safety managers, and construction workers who smoke. To be eligible, construction workers need to be at least 18 years old, have smoked an average of five or more cigarettes daily for the past year, and be ready to make a serious attempt to quit within the next 30 days.
Participants can expect to receive support and training in smoking cessation methods. Company leaders and safety managers will play a key role in helping develop and implement the program. If you are a construction worker, safety manager, or company leader who is interested in making a positive change in your workplace, this trial may be a great opportunity to help yourself and your colleagues quit smoking for good.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Company leaders:
- • ≥ 18 years
- • Involved in decision making
- • Willing to participate in the implementation development and evaluation
- Safety Managers:
- • ≥ 18 years
- • Be a safety manager
- • No plans to leave the company within the next year
- • Bilingual
- • Willing to receive training in smoking cessation treatment
- • Willing to deliver the smoking cessation treatment to workers
- Construction Workers:
- • Be a construction worker
- • ≥ 18 years
- • Have smoked on average 5 or more cigarettes daily for the past year
- • Willing to make a serious quit attempt in the next 30 days
- • Planning to stay in the company for the next 6 months
- • Own a telephone and plan to keep it active for the next 12 months
- Exclusion Criteria:
- Safety Managers:
- • - Current cigarette smoker
About University Of Miami
The University of Miami, a leading academic institution, is dedicated to advancing medical research and improving patient care through innovative clinical trials. With a commitment to excellence in education and research, the university fosters collaboration among multidisciplinary teams to explore new therapies and treatment modalities. Its extensive clinical programs are supported by state-of-the-art facilities and a diverse patient population, enabling the exploration of cutting-edge solutions to complex health challenges. The University of Miami is poised to contribute significantly to the field of medicine through its rigorous scientific inquiry and a steadfast commitment to ethical research practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Miami, Florida, United States
Patients applied
Trial Officials
Taghrid Asfar, MD
Principal Investigator
tasfar@miami.edu
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported